首页> 外文期刊>Biopharmaceutics and Drug Disposition >The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats - in vitro and in vivo pharmacokinetic studies.
【24h】

The outstanding metabolic stability of a 14C-labeled beta-nonapeptide in rats - in vitro and in vivo pharmacokinetic studies.

机译:大鼠体内14C标记的β-九肽的出色代谢稳定性-体外和体内药代动力学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

In vitro studies: In CaCo-2 cell monolayers the beta-nonapeptide H(beta-HAla-beta-HLys-beta-HPhe)(3)-OH.4HCl (1), (14)C-labeled on both C atoms of the CH(2)-CO moiety of the central beta-HPhe residue, showed a low intrinsic permeability (<1%) and is subject to a prominent efflux system. The beta-peptide (1) binds to human and rat plasma protein in vitro independent of the concentration of 1 and of the species (30-36% bound fraction at 50, 500, and 5000 ng/ml), and has only low affinity for the corresponding blood cells (less than 5% of compound 1 in blood cells).In vivo studies: The in vivo pharmacokinetic characteristics after i.v. administration of 5 mg/kg (to male rats and to bile-duct-operated rats) were: (i) negligible in vivo biotransformation of 1 (in urine, plasma and feces unchanged 1 represented virtually the only compound-related molecule); (ii) rapid initial decline (0-8 h post dose) of levels of compound 1 in blood and plasma followed by a slower decline (8-96 h post dose); (iii) in non-operated animals after 96 h only 38% of the dose was excreted and after 168 h 49% of the dose was found remaining in the carcass; elimination through the intestine wall represented the major elimination pathway in non-operated animals while in bile-duct-cannulated animals biliary excretion was not found to contribute substantially to elimination (iv) quantitative whole-body autoradioluminography (QWBAL) investigations revealed that the kidney was by far the most important target organ of distribution; other tissues with high concentrations of compound-related radioactivity were cartilage, lymph nodes, and liver, whereas lowest levels were found in white fat and in the brain. After p.o. administration (10 mg/kg) negligible radioactivity was observed in the systemic circulation, indicating negligible absorption; essentially the entire oral dose was recovered unchanged in feces collected over a period of 96 h.
机译:体外研究:在CaCo-2细胞单层中,β-九肽H(β-HAla-β-HLys-β-HPhe)(3)-OH.4HCl(1),(14)C标记在两个C原子上中央β-HPhe残基的CH(2)-CO部分显示出较低的固有渗透率(<1%),并受到显着的外排系统的影响。 β肽(1)在体外与人和大鼠血浆蛋白结合,而与1和该物种的浓度无关(在50、500和5000 ng / ml时为30-36%的结合级分),并且亲和力很低相应的血细胞(血细胞中少于化合物1的5%)。体内研究:静脉注射后的体内药代动力学特征(对雄性大鼠和经胆管操作的大鼠)5 mg / kg的给药是:(i)1的体内生物转化率可以忽略不计(在尿液,血浆和粪便中,不变的1实际上代表了唯一与化合物相关的分子); (ii)血液和血浆中化合物1的水平迅速开始下降(给药后0-8小时),然后缓慢下降(给药后8-96小时); (iii)在非手术动物中,在96小时后仅排泄了38%的剂量,而在168小时后发现遗体中残留了49%的剂量;在非手术动物中,通过肠壁清除是主要的清除途径,而在胆管插管动物中,未发现胆汁排泄对清除有实质性贡献。(iv)定量全身放射自显影(QWBAL)研究表明,肾脏被排除在外。迄今为止最重要的分配目标机构;与化合物相关的放射性高浓度的其他组织是软骨,淋巴结和肝脏,而在白色脂肪和大脑中的含量最低。下午之后全身循环中观察到的给药(10 mg / kg)放射性可忽略不计,表明吸收可忽略不计;基本上,整个口服剂量在96小时内未改变地恢复到粪便中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号